Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | PIK3CA |
Variant | E545D |
Impact List | missense |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | PIK3CA E545D is a hotspot mutation that lies within the PIK helical domain of the Pik3ca protein (UniProt.org). E545D results in increased transformation ability in two different cell lines in culture (PMID: 29533785), and therefore, is predicted to lead to a gain of Pik3ca protein function. |
Associated Drug Resistance | |
Category Variants Paths |
PIK3CA mutant PIK3CA act mut PIK3CA E545D PIK3CA mutant PIK3CA exon10 PIK3CA E545X PIK3CA E545D |
Transcript | NM_006218.4 |
gDNA | chr3:g.179218305G>C |
cDNA | c.1635G>C |
Protein | p.E545D |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_006218 | chr3:g.179218305G>T | c.1635G>T | p.E545D | RefSeq | hg38 |
XM_006713658.5 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
NM_006218 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
XM_011512894.2 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
XM_006713658 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
XM_011512894 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
NM_006218.4 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
XM_006713658.4 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
NM_006218.3 | chr3:g.179218305G>C | c.1635G>C | p.E545D | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PIK3CA E545D | Her2-receptor negative breast cancer | predicted - sensitive | HS-10352 | Case Reports/Case Series | Actionable | In a Phase I trial, HS-10352 treatment resulted in an objective response rate (ORR) of 27.8% (5/18, all partial responses), disease control rate (DCR) of 55.6%, and median progression-free survival (mPFS) of 3.9 mo in HR-positive, ERBB2 (HER2)-negative advanced breast cancer patients overall, and in the 6mg group led to an ORR of 66.7% and DCR of 83.3%, with an ORR of 75.0% (3/4) and DCR of 100% in patients with PIK3CA mutations (E542K, E545K, E545D, H1047L, H1047R) (PMID: 38037839; NCT04631835). | 38037839 |